Lidocaine selectively blocks abnormal impulses arising from noninactivating Na channels.
Abnormal, repetitive impulse firing arising from incomplete inactivation of Na+ channels may be involved in several diseases of muscle and nerve, including familial myotonias and neuropathic pain syndromes. Systemic local anesthetics have been shown to have clinical efficacy against myotonias and some forms of neuropathic pain, so we sought to develop an in vitro model to examine the cellular basis for these drugs' effects. In frog sciatic nerves, studied in vitro by the sucrose-gap method, peptide alpha-toxins from sea anemone (ATXII) or scorpion (LQIIa) venom, which inhibit Na+ channel inactivation, induced repetitively firing compound action potentials (CAPs) superimposed on a plateau depolarization lasting several seconds. The initial spike of the CAP was unaffected, but the plateau and repetitive firing were strongly suppressed by 5-30 microM lidocaine. Lidocaine caused a rapid, concentration-dependent decay of the plateau, quantitatively consistent with blockade of open Na(+) channels. Early and late repetitive firing were equally suppressed by lidocaine with IC50 = 10 microM. After washout of lidocaine and LQIIa, the plateau and repetitive firing remained for > 1 h, showing that lidocaine had not caused dissociation of channel-bound alpha-toxin. These findings indicate that therapeutic concentrations of lidocaine can reverse the "abnormal" features of action potentials caused by non-inactivating Na+ channels without affecting the normal spike component.
Khodorova
A
A
Department of Anesthesiology, Pain Research Center, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.
Meissner
K
K
Leeson
S
S
Strichartz
G R
GR
D000779:Anesthetics, Local / Q000494:pharmacology*; D000818:Animals; D001551:Benz(a)Anthracenes / Q000633:toxicity; D004558:Electric Stimulation; D066298:In Vitro Techniques; D036341:Intercellular Signaling Peptides and Proteins; D008012:Lidocaine / Q000494:pharmacology*; D009412:Nerve Fibers / Q000187:drug effects; D009431:Neural Conduction / Q000187:drug effects*; D010455:Peptides / Q000633:toxicity; D011894:Rana pipiens; D026941:Sodium Channel Blockers; D019789:Tetraethylammonium / Q000494:pharmacology
D000779:Anesthetics, Local; D001551:Benz(a)Anthracenes; D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides; D026941:Sodium Channel Blockers; C077585:leiurutoxin III; C050234:altertoxin II; D019789:Tetraethylammonium; D008012:Lidocaine